1. Flow chart patient inclusion.
Flow chart patient inclusion. Patients with AACM data were collected from the hospital-based registry of DCM families (cohort I) and two hospital-based registries of patients with cancer (adult- or childhood-onset) treated with systemic cancer therapy (cohort II-adult-onset patients and cohort III-childhood-onset patients). AACM, anthracycline-associated cardiomyopathy; DCM, dilated cardiomyopathy; FU, follow-up; LVEF, left ventricular ejection fraction; SF, shortening fraction; WMSI, wall motion score index.* Two patients from a previously published study.13 †Using the cut-off values of ≤450 mg/m2 for doxorubicin and ≤600 mg/m2 for epirubicin, we aimed to include patients who received at most the submaximal dose of anthracyclines.
Marijke Wasielewski et al. Open Heart 2014;1:e000116
©2014 by British Cardiovascular Society